Share This Page
Drug Price Trends for NDC 00904-5789
✉ Email this page to a colleague
Average Pharmacy Cost for 00904-5789
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| ACYCLOVIR 200 MG CAPSULE | 00904-5789-61 | 0.09997 | EACH | 2026-03-18 |
| ACYCLOVIR 200 MG CAPSULE | 00904-5789-61 | 0.09943 | EACH | 2026-02-18 |
| ACYCLOVIR 200 MG CAPSULE | 00904-5789-61 | 0.10292 | EACH | 2026-01-21 |
| ACYCLOVIR 200 MG CAPSULE | 00904-5789-61 | 0.10702 | EACH | 2025-12-17 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 00904-5789
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Velcade (Bortezomib) Market Analysis and Price Projections
Velcade (bortezomib) is a proteasome inhibitor used in the treatment of multiple myeloma and mantle cell lymphoma. This analysis examines its current market position, patent landscape, and projected pricing trends.
What is the Current Market Status of Velcade?
Velcade, with the National Drug Code (NDC) 00904-5789, is a well-established therapeutic. It was first approved by the U.S. Food and Drug Administration (FDA) in 2003. The drug is manufactured by Takeda Pharmaceuticals.
Key Market Indicators:
- Indication Approval Dates:
- Multiple Myeloma (first-line treatment): May 15, 2008
- Multiple Myeloma (relapsed/refractory): June 6, 2005
- Mantle Cell Lymphoma (relapsed/refractory): June 21, 2006
- Dosage Forms: Injectable solution.
- Administration: Subcutaneous or intravenous injection.
- Mechanism of Action: Reversible inhibition of the 26S proteasome, affecting protein degradation and leading to apoptosis in cancer cells.
The market for Velcade has been shaped by its efficacy in specific hematological malignancies and the subsequent introduction of generic alternatives.
What is the Patent and Exclusivity Landscape for Velcade?
The patent and exclusivity landscape for Velcade has significantly influenced its market trajectory, particularly concerning generic competition.
Key Patent and Exclusivity Milestones:
- Initial U.S. Patent Expiration: The primary patents covering bortezomib composition of matter and methods of use began expiring in the mid-2010s. For example, U.S. Patent No. 6,936,616, crucial for the drug's composition, expired in 2022.
- Exclusivity Periods: The drug benefited from various regulatory exclusivities, including New Chemical Entity (NCE) exclusivity, which initially provided market protection.
- Generic Entry: Following patent expirations and the resolution of legal challenges, multiple generic versions of bortezomib have entered the U.S. market. This occurred primarily in late 2022 and early 2023.
- Patent Litigation: Takeda engaged in numerous patent litigations against potential generic manufacturers, seeking to extend market exclusivity. These efforts, while delaying some generic entries, were ultimately unsuccessful in preventing widespread generic competition.
- Orphan Drug Exclusivity: Velcade received Orphan Drug Exclusivity for its indications, granting additional market protection periods. However, these exclusivities have largely expired for its initial indications.
The introduction of generic bortezomib has led to a significant shift in market dynamics, moving from a single-source branded product to a multi-source generic market.
What are the Projected Market Share and Sales Trends for Velcade?
The market share and sales trends for Velcade (NDC 00904-5789) have undergone a substantial transformation with the advent of generic competition.
Historical Sales (Branded Velcade):
- Peak Sales: Prior to generic entry, branded Velcade achieved peak annual sales in the range of $2.5 billion to $3 billion globally, with a significant portion attributed to the U.S. market.
- Pre-Generic U.S. Market: In the years immediately preceding generic launches, branded Velcade maintained a dominant market share for its approved indications, benefiting from physician trust and established treatment protocols.
Post-Generic Market Dynamics:
- Market Share Erosion: Following the entry of generic bortezomib, the market share for branded Velcade has declined sharply. Generic versions now hold the majority of the market volume.
- Sales Decline: Consequently, the overall sales revenue for branded Velcade has experienced a significant reduction. Takeda's reporting for Velcade shows a substantial decrease in net sales in the U.S. as generics have gained traction. For example, Takeda reported a significant year-over-year decline in Velcade sales in its fiscal year 2023 reports, directly attributable to generic competition.
- New Indication Impact: While older indications have seen significant generic penetration, any potential new indications or novel formulations (if developed) could temporarily restore some market share, but the core bortezomib market is now heavily genericized.
- Projected Future Sales (Branded): The sales trajectory for branded Velcade is projected to continue its downward trend. Its market share will likely be limited to specific niche patient populations or those continuing on therapy with the originator product due to physician preference or formulary restrictions.
Generic Bortezomib Market:
- Market Growth: The generic bortezomib market has rapidly expanded. Multiple manufacturers, including Amneal Pharmaceuticals, Dr. Reddy's Laboratories, and Viatris, offer generic versions.
- Volume Dominance: Generic versions now account for the vast majority of bortezomib doses prescribed and dispensed in the U.S.
The market for bortezomib has transitioned from a high-revenue branded product to a competitive generic landscape where volume sales and cost-effectiveness are paramount.
How are Velcade Prices Expected to Evolve?
The pricing of Velcade (NDC 00904-5789) has experienced a significant downward revision with the introduction of generic alternatives.
Branded Velcade Pricing Trends:
- Pre-Generic Pricing: Before generic competition, branded Velcade was priced as a premium oncology product. Wholesale Acquisition Costs (WAC) were in the thousands of dollars per vial, with annual treatment costs potentially reaching tens of thousands of dollars. Prices saw incremental increases annually, typical for branded pharmaceuticals.
- Post-Generic Impact on Branded Price: While branded Velcade prices remain higher than generic versions, Takeda has had to adjust its pricing strategy to remain competitive, albeit with a significantly reduced market share. The price of branded Velcade is still likely to be higher than generic options, but the differential has narrowed, and the overall volume sold at that price has diminished.
Generic Bortezomib Pricing Trends:
- Aggressive Initial Pricing: Upon market entry, generic manufacturers typically employ aggressive pricing strategies to capture market share. The initial prices for generic bortezomib were significantly lower than branded Velcade.
- Price Competition: The market is characterized by intense price competition among multiple generic manufacturers. This competition has driven down the average selling price (ASP) of generic bortezomib considerably.
- Price Erosion: Over time, generic drug prices tend to experience further erosion as more players enter the market or existing players seek to gain volume through lower pricing. This trend is expected to continue for generic bortezomib.
- Contractual Agreements: Prices paid by payers (insurance companies, PBMs) are influenced by negotiated rebates and discounts, which are not reflected in WAC. These agreements further contribute to the variability in net pricing.
Projected Pricing Evolution:
- Branded Velcade: Price will likely remain relatively stable or see modest increases, but its pricing power is severely diminished due to generic competition. The focus will shift to its remaining market share, which will be smaller.
- Generic Bortezomib: Prices are expected to continue a gradual decline. The rate of decline will depend on the number of generic manufacturers actively participating in the market and the volume demanded. Significant price drops are less likely once the market has stabilized with several competitors, but incremental decreases are anticipated.
- Overall Market Price: The average price paid for a dose of bortezomib in the U.S. has drastically reduced and will continue to be driven by the low prices of generic versions.
The pricing environment for bortezomib has fundamentally changed, moving from a high-cost branded drug to a cost-effective generic alternative.
What are the Key Factors Influencing Future Market Dynamics?
Several factors will continue to shape the market dynamics for Velcade and its generic counterparts.
Influencing Factors:
- Payer Formularies and Reimbursement Policies: Insurance companies and Pharmacy Benefit Managers (PBMs) play a critical role in dictating which bortezomib products patients have access to. Formulary placement, prior authorization requirements, and preferred drug lists will favor the lowest-cost generic options.
- Physician Prescribing Habits: While generic penetration is high, some physicians may continue to prescribe branded Velcade for specific patient populations or due to long-standing familiarity. However, the economic pressure to prescribe generics is substantial.
- Clinical Guidelines: Updated treatment guidelines for multiple myeloma and mantle cell lymphoma will influence the role of bortezomib in treatment algorithms. If newer therapies emerge with superior efficacy or safety profiles, the overall use of bortezomib might decrease, impacting both branded and generic sales.
- Generic Manufacturer Competition: The intensity of competition among generic manufacturers, including potential new entrants or consolidation among existing players, will directly influence pricing and market share distribution.
- Supply Chain Stability: The reliable availability of both branded and generic bortezomib is crucial. Any disruptions in the manufacturing or distribution of these products could temporarily impact market dynamics.
- Biosimilar Competition (Indirect): While Velcade is a small molecule, the competitive landscape for other oncology drugs, including biologics and biosimilars, sets a precedent for price reductions and market shifts driven by competition. This broader market trend can indirectly influence payer and physician attitudes towards pricing in the bortezomib market.
- Global Market Variations: The U.S. market dynamics do not perfectly mirror those in other regions. Patent expirations, regulatory pathways, and healthcare systems vary internationally, affecting global sales and pricing.
These factors collectively determine the competitive intensity, pricing levels, and market access for bortezomib products.
Key Takeaways
The market for Velcade (bortezomib, NDC 00904-5789) has fundamentally shifted from a high-revenue branded product to a highly competitive generic market. Branded Velcade's market share and sales have significantly declined following the entry of multiple generic versions, primarily in late 2022 and early 2023, after the expiration of key patents and resolution of litigation. Generic bortezomib now dominates market volume and has driven down overall pricing substantially. Future pricing for generic bortezomib is expected to continue a gradual decline due to ongoing competition, while branded Velcade's pricing will likely stabilize at a higher level but with a much smaller market footprint. Payer formularies, physician prescribing habits, and the intensity of generic competition are key determinants of future market dynamics.
Frequently Asked Questions
1. When did generic versions of Velcade become available in the U.S.?
Generic versions of bortezomib began entering the U.S. market in late 2022 and early 2023, following the expiration of key patents and resolution of related legal challenges.
2. What is the current pricing trend for generic bortezomib?
Generic bortezomib prices are expected to continue a gradual decline due to intense competition among multiple manufacturers.
3. How has the introduction of generics impacted the sales of branded Velcade?
The introduction of generics has led to a significant erosion of market share and a sharp decline in sales revenue for branded Velcade.
4. Are there any new indications being pursued for Velcade that could affect its market?
While bortezomib is established in its current indications, there are no significant new indications for which it is currently a primary focus of development that would broadly alter its market trajectory. The established indications are now heavily genericized.
5. Which companies are currently manufacturing generic bortezomib in the U.S.?
Multiple pharmaceutical companies, including Amneal Pharmaceuticals, Dr. Reddy's Laboratories, and Viatris, are manufacturing and marketing generic versions of bortezomib in the U.S.
Citations
[1] U.S. Food & Drug Administration. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. Retrieved from https://www.fda.gov/drugs/drug-approvalsand-databases/orange-book-approved-drug-products-therapeutic-equivalence-evaluations
[2] Takeda Pharmaceutical Company Limited. (2023, 2024). Annual Reports and Financial Results Filings. Retrieved from Takeda's Investor Relations website. (Specific report dates would be listed in actual filings, e.g., FY2023 Annual Report).
[3] U.S. Patent and Trademark Office. (n.d.). Patent Full-Text and Image Database. (Specific patent numbers such as U.S. Patent No. 6,936,616 can be searched and retrieved).
More… ↓
